Northwestern Memorial Healthcare

UHealth-University of Miami Health System has enrolled the first two patients in Aclarion's pivotal CLARITY trial, testing Nociscan technology for chronic low back pain surgical outcomes.

Three prominent Chicago hospitals have formed the Chicago Breast Cancer Research Consortium to conduct collaborative clinical trials for advanced breast cancer patients.

Northwestern Medicine researchers discovered that Zileuton, an FDA-approved asthma drug, nearly eliminated life-threatening allergic reactions in mice by blocking a previously unknown pathway involving the DPEP1 gene.

A multi-center phase 2 clinical trial led by Northwestern Medicine found that Duavee significantly reduced cell growth in breast tissue among 141 postmenopausal women with ductal carcinoma in situ (DCIS).

Keck Medical Center of USC has joined the CLARITY trial to evaluate Aclarion's Nociscan technology, which uses MR Spectroscopy and AI to identify sources of chronic low back pain.

Northwestern Medicine researchers are initiating a seven-year clinical trial to determine if wearable technology can reduce continuous blood thinner use in atrial fibrillation patients, potentially decreasing bleeding risks and improving quality of life.

Sibel Health has closed a $30 million Series C financing round led by the Steele Foundation for Hope with significant participation from Dräger, positioning the company for commercial expansion.

Northwestern Medicine, a leading clinical research institution that conducted over 6,900 studies in 2024, has been selected as the initial site for Aclarion's CLARITY trial investigating Nociscan technology.

Researchers have discovered that SARS-CoV-2 RNA can trigger the development of inducible nonclassical monocytes (I-NCMs), a unique type of immune cell with anti-cancer properties.

Northwestern Medicine researchers observed cancer regression in some patients who experienced severe COVID-19, suggesting a potential link between the immune response and cancer cell death.